ProSkelia SAS

In Vitro Diagnostics Joint Arrangements / In Vitro Diagnostics Immunicon Corp. Immunicon (molecular-based cancer diagnostics) netted $27.9mm through the private placement of $30mm principal amount

Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging—mostly through the transformation of existing pharma asse

Europe's financing and regulatory environment means that it has been, and will continue to be, very difficult to build Amgen-style big biotech from scratch here. But a sustainable industry of large bi

The merger of the UK's Strakan with ProSkelia of France will create a uniquely European firm, tying together a Big Pharma spin-out with a small specialty group focused on just a handful of Europe's di